The global impairment of mature microRNAs (miRNAs) is emerging as a common feature of human tumors. One interesting scenario is that defects in the nuclear export of precursor miRNAs (pre-miRNAs) might occur in transformed cells. Exportin 5 (XPO5) mediates pre-miRNA nuclear export and herein we demonstrate the presence of XPO5-inactivating mutations in a subset of human tumors with microsatellite instability. The XPO5 genetic defect traps pre-miRNAs in the nucleus, reduces miRNA processing, and diminishes miRNA-target inhibition. The XPO5 mutant form lacks a C-terminal region that contributes to the formation of the pre-miRNA/XPO5/Ran-GTP ternary complex and pre-miRNAs accumulate in the nucleus. Most importantly, the restoration of XPO5 functions reverses the impaired export of pre-miRNAs and has tumorsuppressor features.
INTRODUCTION
MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by targeting messenger RNA (mRNA) transcripts. MiRNAs play important roles in several cellular processes by simultaneously controlling the expression levels of hundreds of genes (He and Hannon, 2004; Bartel, 2004; . In human cancer, miRNA expression profiles differ between normal tissues and derived tumors and between tumor types (Lu et al., 2005; Volinia et al., 2006) , and it has been shown that miRNAs can act as oncogenes or tumor suppressors (Esquela-Kerscher and Slack, 2006; Hammond, 2007) . Importantly, an miRNA expression profile of human tumors has emerged that is characterized by a defect in miRNA production and global miRNA downregulation (Lu et al., 2005; Calin and Croce, 2006; Gaur et al., 2007) . Recent studies have provided possible mechanisms that could explain this miRNA deregulation in cancer: failure of miRNA posttranscriptional regulation (Thomson et al., 2006) , CpG island promoter hypermethylation-associated transcriptional silencing (Saito et al., 2006; Lujambio et al., 2007) , transcriptional repression by oncogenic factors (Chang et al., 2008) , and mutational impairment of Significance MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by inhibiting target messenger RNA (mRNA). Data from numerous studies indicate that miRNAs play a critical role in tumorigenesis. The production of mature miRNAs is accomplished via an enzymatic pathway that can go awry at various steps. These defects can explain the reported downregulation of miRNAs in human cancer. Herein, we show that a subset of tumors from the colon, stomach, and endometrium harbor inactivating mutations of XPO5, a gene critical to the export of the immature precursor miRNAs (pre-miRNAs) from the nucleus to the cytosol. The re-expression of the wild-type protein rescues the aberrant phenotype and has tumorsuppressor properties. This last finding might also have therapeutic applications.
the TARBP2 miRNA processing gene . This last finding is particularly relevant because if the factors involved in miRNA processing pathways are themselves targets of genetic disruption, they might represent another class of tumorsuppressor genes. In this regard, there is an enhancement of tumorigenesis upon depletion of DICER1 in human cells (Kumar et al., 2007) and heterozygous deletion of DICER1 in mice (Kumar et al., 2007 Lambertz et al., 2010) . Moreover, reduced DICER1 expression occurs in lung and ovarian tumors (Karube et al., 2005; Merritt et al., 2008) . Under these circumstances, DICER1 might be described as a haploinsufficient tumor-suppressor gene that is heterozygously deleted in cancer ). Most importantly, have identified DICER1 germline mutations in an inherited cancer syndrome, familial pleuropulmonary blastoma.
The biogenesis of miRNAs in mammalian cells involves both nuclear and cytoplasmic processing (Lee et al., 2002) catalyzed by ribonuclease III (RNase III)-like endonucleases that recognize double-stranded RNAs. miRNAs are initially transcribed as long RNAs, termed primary miRNAs (pri-miRNAs) , that contain the mature miRNA as one arm of an RNA stem-loop (Lee et al., 2002) . This stem-loop is excised by the nuclear RNase III enzyme DROSHA to give an $65 nt RNA hairpin, bearing a 2 nt 3 0 overhang, termed a precursor-miRNA (pre-miRNA) (Zeng and Cullen, 2004) . The pre-miRNAs generated in the nucleus require further processing in the cytoplasm, and so the nucleocytoplasmic transport of pre-miRNAs is essential for the maturation process of the miRNAs (Yi et al., 2003; Bohnsack et al., 2004; Kim, 2004; Lund et al., 2004) .
One of the key elements in the nuclear export of pre-miRNAs is Exportin-5 (XPO5) (Lund et al., 2004) . XPO5 is a member of the karyopherin b family related to human export receptor CRM1 that uses the GTPase Ran to control cargo association (Smith et al., 2002; Bohnsack et al., 2004) . Nuclear export of pre-miRNAs is tightly regulated in normal cells and its disruption would also cause the observed phenotype of global downregulation of mature microRNAs in cancer cells. Strikingly, a recent report has demonstrated that some pre-miRNAs are retained in the nucleus of several cancer cell lines , reinforcing the hypothesis that genetic defects in the pre-miRNA nuclear export genes might occur in human tumors.
Here, we investigated whether genes involved in the export of the pre-miRNAs, such as XPO5, undergo loss-of-function mutations in human tumors and the functional significance of such inactivation in nucleocytoplasmic pre-miRNA shuttling and cellular transformation.
RESULTS

Detection of an XPO5-Inactivating Mutation in Human Cancer Cells
In order to explore the existence of inactivating mutations in the process of nucleocytoplasmic export of pre-miRNAs, we decided to consider tumors that exhibit microsatellite instability, in the contexts of hereditary nonpolyposis colon cancer (HNPCC) associated with germline mutations in the mismatch repair genes and of sporadic cancers associated with hMLH1 inactivation by promoter CpG island methylation. Tumors with microsatellite instability progress along a genetic pathway with a high rate of insertion and deletion mutations in mononucleotide repeats, which often results in the generation of premature stop codons. Illustrative target genes include the growth control gene TGFBR2 (Markowitz et al., 1995) and the proapoptotic gene BAX (Rampino et al., 1997) .
We first screened six colorectal (Co115, RKO, SW48, LoVo, HCT-15, DLD-1, and HCT-116), four endometrial (SKUT-1, SKUT-1B, AN3CA, and HEC1B), and two gastric (SNU-1 and SNU-638) cancer cell lines with microsatellite instability for the presence of mutations in all the exonic mononucleotide repeats present in the coding sequences of the two main genes involved in the export of the pre-miRNAs from the nucleus: exportin 5 (XPO5) and Ras-related nuclear protein (RAN). We detected only wild-type sequences for RAN ( Figure S1 ) but found a frameshift mutation in XPO5: the insertion of an ''A'' in an (A) 7 coding microsatellite repeat of exon 32 (position 3546 bp) in the colorectal cancer cell lines HCT-15 and DLD-1 ( Figure 1A ). The insertion generates a premature termination codon at position 3582 bp. The protein originated from the mutated transcript has altered amino acids 1181-1192 and truncated amino acids 1193-1205. The mutation was present in 24 of 48 (50%) and 25 of 48 (52%) single clone sequences obtained from genomic DNA for HCT-15 and DLD-1, respectively. The same proportion of mutant alleles was found when we used cDNA as the starting material, which indicates that they are heterozygous mutations. The FISH analysis showed that the two alleles were retained in both cancer cell lines ( Figure S1 ).
The analyses of XPO5 expression by western blot in the total protein extracts from mutant cell lines HCT-15 and DLD-1 demonstrated the presence of the truncated form of the XPO5 protein ( Figure 1B ; Figure S1 ) in addition to the wild-type form. The mutated XPO5 protein was not present in the wild-type cell lines SW48, HCT-116, and RKO. Most interestingly, when we analyzed nuclear and cytoplasmic fractions separately for XPO5 protein by western blot in the three XPO5-proficient cells (RKO, HCT-116, and SW48) and two XPO5 mutated cells (HCT-15 and DLD-1), we found that the truncated form of the XPO5 protein was exclusively present in the nuclear fraction of HCT-15 and DLD-1 cell lines ( Figure 1B) . To reinforce the protein localization results obtained by western blot, we carried out immunocytochemistry for the XPO5 protein and observed that in mutated cells (HCT-15 and DLD-1) the XPO5 protein mainly accumulated in the nucleus ( Figure 1B) . XPO5 wild-type cells (HCT-116 and RKO) show XPO5 staining that spreads equally throughout the nucleus and the cytoplasm ( Figure 1B ).
The XPO5 Mutation Traps Precursor microRNAs in the Nucleus, Decreases Processing Efficiency, and Diminishes Target Inhibition by miRNAs Once the presence of an XPO5 mutation associated with abnormal protein localization in cancer cells had been confirmed, it became very important to establish, whether the subcellular distribution of pre-miRNAs was affected as well as their processing efficiency, the amount of pre-miRNA that is transformed in its mature form (Experimental Procedures). We first assessed pre-miRNA cellular localization by the study of 24 pre-miRNAs analyzed by qRT-PCR (Schmittgen et al., 2004) in isolated nuclear and cytoplasmic fractions. For all the studied pre-miRNAs, we observed a nuclear accumulation of these molecules in XPO5 mutant cells (HCT-15 and DLD-1) ( Figure 1C ), while in XPO5 wild-type cells (RKO and HCT-116) the pre-miRNAs were found mainly in the cytoplasmic fraction ( Figure 1C ). Northern blot analysis for miRNA-125-b confirmed its inefficient pre-miRNA processing in XPO5 mutant versus wild-type cells ( Figure 1D ). Furthermore, we observed that XPO5 mutant cells featured an overall reduction in the efficiency of processing each of the 24 pre-miRNAs molecules, defined as the ratio of mature to precursor miRNA determined by qRT-PCR, relative to XPO5 wild-type cells ( Figure S1 ). Interestingly, XPO5 might also be an auxiliary exporter of transfer RNAs (tRNAs) (Bohnsack et al., 2002; Calado et al., 2002) , in parallel to the principal tRNA exporter Exportin-T (XPOT) (Kö hler and Hurt, 2007) . We did not observe an accumulation of tRNA
Met assessed by northern blot in XPO5 mutant cells (HCT-15 and DLD-1) in comparison to wild-type cells (RKO and HCT-116) ( Figure 1D ). However, this observation does not rule out that other tRNAs are affected. In Figure S1 .
fact, XPOT and XPO5 bind quite complementary sets of tRNAs (Bohnsack et al., 2002) . To strengthen the evidence of a link between XPO5 mutation and the impaired protein shuttling between nucleus and cytoplasm and the defective processing of pre-miRNAs observed, we reconstituted XPO5 function in XPO5 mutant cancer cells (HCT-15) ( Figure S2 ). XPO5 levels in the ectopically expressing cells in comparison to the endogenous levels in the sham/control transfected cells are shown in Figure S2 . Transfection of an N-terminal flag-tagged wild-type form of XPO5 protein (XPO5 WT ) in HCT-15 cells showed that the wild-type transfected protein localizes in the nucleus and cytoplasm ( Figure 2A) . However, the transfection of a N-terminal flag-tagged construct carrying the described XPO5 mutation (XPO5 Mut ) in HCT-15 cells shows an XPO5 protein that it is located inside the nucleus and no signal is seen in the cytoplasm (Figure 2A ). Wild-type endogenous XPO5 localization was unaffected upon mock transfection ( Figure S2 ). Because the approach described looks at proteins steady-state levels, we also formally proved that FLAG-XPO5 Mut is trapped in the nucleus using the heterokaryon approach (Lee et al., 1996) transfected HCT-116 fused cells ( Figure 2B ). Most importantly, XPO5 mutant cells transfected with the wild-type protein underwent a relocation of pre-miRNAs from the nucleus to the cytosol ( Figure 2C ). Northern blot analyses for miRNA-125-b and miRNA-26-a confirmed the described results ( Figure 2D ). XPO5 wild-type transfection was associated with an increased processing capacity for the 24 pre-miRNAs determined by qRT-PCR ( Figure S2 ). Transfection of the mutant form of XPO5 in HCT-15 cells was unable to rescue the phenotype: pre-miRNAs were essentially located in the nucleus ( Figure 2C ) and no increase in pre-miRNA processing efficiency was observed ( Figure S2 ), implying the loss of function features of the identified mutation. Using primers specific for the 30 pri-miRNAs that originate the studied 24 pre-miRNAs (details in Experimental Procedures), we have observed that pri-miRNA levels did not change upon transfection of the wild-type or mutant XPO5, supporting that the mutation only affects pre-miRNAs (). tRNA Met ( Figure 2D ) levels were also unchanged upon transfection of the wild-type or mutant XPO5. In sharp contrast, the stable downregulation of XPO5 by independent transfection of three different short-hairpins that targets XPO5 in cells with wild-type XPO5 (RKO) ( Figure 3A ; Figure S3 ) 
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Deficient Export of Pre-miRNAs was associated with enhanced retention of the studied 24 premiRNAs inside the nucleus ( Figure 3B ; Figure S3 ). Northern blot for miRNA let-7a confirmed the described results ( Figure 3C ). An impairment of pre-miRNA processing efficiency was also observed upon XPO5 depletion ( Figure S3 ). siRNA against the mutant XPO5 transcript in HCT-15 and DLD-1 cells did not cause any evident effect in pre-miRNA processing capacity ( Figure S3 ). Pri-miRNAs ( Figure S3 ) and tRNA Met ( Figure 3C ) levels were unchanged upon XPO5 depletion. Furthermore, we were able to mimic the mutant XPO5 phenotype using wheat germ agglutinin (WGA). WGA blocks nuclear pore complexes by binding to GlcNac-modified nucleoporins (Mohr et al., 2009) . Using electroporation to deliver WGA into the cells (Todorova, 2009) , we observed that XPO5 wild-type cells (RKO and HCT-116) underwent confinement of the XPO5 protein in the nucleus ( Figure 3D ), nuclear accumulation of pre-miRNAs ( Figure 3E , left graph), and decreased pre-miRNA processing efficiency ( Figure 3E , right graph) that closely resemble the phenotype observed in XPO5 mutant cells.
We also wondered whether the impaired nuclear export associated with XPO5 mutation had an impact on the inhibitory efficiency of miRNA target genes. To address this issue, we stably transfected wild-type, mutant and reconstituted XPO5 cells with pRS-GFPneo-miR-15-16, a vector that produces a pre-miRNA that needs to be nuclear exported in order to be processed correctly and give rise to its mature forms (miR-15-a and miR-16-1) ( Figure 3F ). To show interaction of the mature miRNAs with its target 3 0 UTR, we transiently transfected to the described cells the 3 0 UTR of the oncogene Bcl2 under a luciferase reporter, a known and validated target of miR-15-a/16-1 (Calin et al., 2008) . We observed that luciferase activity was significantly decreased only in XPO5 wild-type (RKO) and XPO5 colorectal cancer cells. No significant effect was demonstrated in XPO5 mutant cells such as DLD-1 and HCT-15 ( Figure 3G ). Most importantly, luciferase activity was also unaffected in HCT-15 cells transfected with the mutant form of XPO5 (XPO5 Mut )
( Figure 3G ). Consistent with these data, we also observed that, following stable EGFP transfection in XPO5 WT and XPO5 Mut -HCT-15 cells ( Figure S3 ), a short-hairpin against EGFP was only able to achieve complete silencing in XPO5 WTrestored cells ( Figure S3 ). qRT-PCR on EGFP mRNA was used as a quantitative measure of the shRNA efficiency ( Figure S3 ).
XPO5 Mutant Form (XPO5
Mut ) and the Functional Impairment of the Pre-miRNA/XPO5/Ran-GTP Complex Once we had demonstrated that XPO5 mutant cells had a defect with respect to exporting pre-miRNAs out of the nucleus and consequently an impaired processing efficiency, we sought to determine why the mutant form of the XPO5 protein is trapped inside the nucleus. It is well documented that pre-miRNAs are specifically bound by XPO5, acting in concert with the GTPbound form of the Ran cofactor (Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 2003) . Since cargo binding to XPO5 is promoted by Ran-GTP, we decided first to establish whether Ran could bind the XPO5 Mut form. We performed GST pulldown experiments with recombinant proteins purified from Escherichia coli in the absence or presence of the cargo, the pre-miRNA molecule pre-let-7a. First, as expected, we observed that the addition of pre-let-7a increased the affinity of the polyhistidine-tagged XPO5 WT to bind GST-Ran in a GTP-dependent manner ( Figure 4A , lanes 1 and 2). However, the polyhistidinetagged XPO5 mutant form, although also able to bind to GSTRan in a GTP-dependent manner, did not show any cooperativity for Ran binding in the presence of cargo (pre-let-7a) ( Figure 4A , lanes 3 and 4). As a negative control, we used a construct lacking 108 amino acids at the N-terminal domain of XPO5 (XPO5 D108 ) that is responsible for Ran-GTP coupling (Brownawell and Macara, 2002) (Figure 4A , lanes 5 and 6). Our findings are in agreement with previous observations that described Ran/GTP coupled to the N-terminal of XPO5 protein (Brownawell and Macara, 2002) . This domain is not altered in the XPO5
Mut form that we describe herein. Knowing that a ternary complex of pre-miRNA/XPO5/Ran-GTP is necessary for efficient nuclear export (Zeng and Cullen, 2004) , we decided to analyze the capacity of XPO5 WT and XPO5 Mut forms to bind pre-miRNAs molecules using the pre-miRNA molecule pre-let-7a. We transfected a 3 0 -biotin labeled synthetic pre-let-7a in XPO5 mutant HCT-15 cells stably transfected with the empty vector (pcDNA3.1+), the FLAG-XPO5 wild-type (FLAG-XPO5
WT ) and the FLAG-XPO5 mutant (FLAG-XPO5 Mut ) forms, followed by FLAG-XPO5 protein and pre-let-7a cellular localization by immunodetection of Flag and biotin, respectively. In empty vector transfected cells, we observed that pre-let-7a is maintained within the nucleus after transfection during a 2 hr period (Figure 4B , left panels and left graph). In HCT-15 cells with reconstituted XPO5 activity (FLAG-XPO5
WT ), however, we observed efficient export of the labeled pre-let-7a into the cytoplasm 1 hr after transfection and disappearance of the biotin signal in the cytoplasm 2 hr after transfection ( Figure 4B ). Furthermore, XPO5
WT flag-tagged protein was found in the same cellular compartment with pre-let-7a throughout the 2 hr after transfection translocating from the nucleus to the cytoplasm 1 hr after transfection ( Figure 4B ). The same results for XPO5 wild-type context had been reported for pre-miR-31 export (Bohnsack et al., 2004) . When the same assay was developed on HCT-15 FLAG-XPO5
Mut transfected cells, pre-let-7a was not efficiently transported into the cytoplasm, and 2 hr after transfection there was still biotin labeling inside the nucleus ( Figure 4B ). Results of pre-let-7a levels obtained by qPCR of fractionated nuclear and cytoplasmic samples confirmed the immunocytochemistry data ( Figure 4C ). Furthermore, XPO5
Mut flag-tagged protein showed no translocation to the cytoplasm but stayed in the nucleus for the 2 hr period ( Figure 4B , right panel antiflag labeling). As a control for the transfection procedure, the staining for the XPO5 endogenous protein demonstrated that its main nuclear localization in the HCT-15 mutant cells was unchanged right before and immediately after pre-let-7a transfection ( Figure S4 ). Once the impairment of pre-let-7a export mediated by a defective XPO5 protein had been demonstrated, we tested the capacity of the XPO5 mutant form to bind pre-let-7a in a Ran-GTP-dependent manner. For this purpose, we used the 3 0 biotin-labeled synthetic pre-let-7a to incubate with purified, recombinant His-tagged human XPO5
WT , XPO5 Mut , and recombinant Ran in the presence of GTP. We determined by gel shift analysis that the biotin labeled pre-let-7a did not bind XPO5
Mut in the presence of Ran and GTP ( Figure 4D ). However, pre-let-7a formed a readily detectable complex when incubated with XPO5
WT ( Figure 4D ). To reinforce the specificity of the formed RNA-protein complex, we wondered whether unlabeled competitor RNA would block complex formation if added in excess, and whether a supershift could be observed when the antihistidine antibody was added to the reaction. Formation of the pre-let-7a/XPO5/Ran-GTP complex was indeed inhibited when the unlabeled competitor RNA was used and a supershift was observed when antihistidine antibody was added to the reaction ( Figure 4D ). Most importantly, the same binding results were obtained by calorimetric assays ( Figure 4E ). The precursor let-7a molecule reacts exothermically (DH = À9.08 Kcal/mol) with XPO5 WT protein in the presence of Ran-GTP, while no reaction was observed between the XPO5 Mut form and the precursor miRNA molecule ( Figure 4E ). The XPO5 WT and XPO Mut proteins did not bind pre-let-7a in the absence of Ran-GTP ( Figure 4E ). We also analyzed if the mutant XPO5 protein was in any way able to interfere in the binding of the wild-type XPO5 protein to its pre-miRNA substrates. Using both EMSA and calorimetric studies to assess the binding of the wild-type XPO5 protein to pre-let-7a in the presence of the XPO5 mutant protein and Ran-GTP, we observed that the binding to the pre-miRNA 
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Deficient Export of Pre-miRNAs substrate was not affected by the presence of the XPO5 mutant protein ( Figure S4 ). Overall, these results suggest that a region in the C-terminal of XPO5 protein is involved in the binding and/or recognition of premiRNAs as a cargo substrate. In XPO5 mutant cells, such as HCT-15 and DLD-1, the protein is not able to load the precursor miRNA molecule, the pre-miRNA/XPO5/Ran-GTP ternary complex cannot be assembled and pre-miRNAs accumulate in the nucleus.
Tumor-Suppressor Features of the XPO5 Protein
Once we had demonstrated how the described XPO5 mutation in cancer cells impaired the export of pre-miRNAs, we wished to determine its contribution to the tumorigenic phenotype. Thus, we took a triple approach to show how XPO5 genetic disruption causes a defect in the expression of mature miRNAs with tumor-suppressor features, how its restoration leads to cancer growth inhibition both in vitro and in vivo, and how XPO5 mutations are present in human primary tumors.
We first analyzed the miRNA expression profile of wild-type (RKO and HCT-116), mutant (HCT-15 and DLD-1), reconstituted (HCT-15 and DLD-1 XPO5 WT ), and mutant transfected (HCT-15
and DLD-1 XPO5 Mut ) XPO5 cell lines using a comprehensive expression miRNA microarray platform that covers 731 miRNAs (Calin et al., 2007) . Among these, the expression of around 50% miRNAs was initially absent in the colorectal cancer cell lines RKO (n = 449), HCT-116 (n = 448), DLD-1 (n = 421), and HCT-15 (n = 398). We used Class Comparison (p < 0.001) to identify the miRNAs differentially expressed between classes, and Class Prediction (p < 0.001, repeated 100 times, K-fold cross-validation method, where K = 10) to identify patterns of miRNAs that can discriminate groups of samples. The two XPO5 mutant cell lines were characterized as having a significant downregulation of 85 miRNAs compared with the two wild-type XPO5 cell lines ( Figure 5A ). Most importantly, the reintroduction of XPO5 in the mutant cells upregulated 114 miRNAs ( Figure 5A , HeatMap) that included 80 of 85 (94%) of the described miRNAs. qRT-PCR was used to validate the microarray data for 11 miRNAs (six miRNAs upregulated in XPO5
WT -transfected cells and five miRNAs with similar levels) ( Figure 5B ). We did not observe any shift in the miRNA expression profile when the XPO5 mutant cells were transfected with the XPO5 Mut form. Strikingly, for these 80 miRNAs downregulated in XPO5 mutant cells and whose expression is restored in reconstituted cells, 76.8% have potential tumor-suppressor features ( Figure 5C ; Medina and Slack, 2008; Spizzo et al., 2009 ). Most importantly, this impairment of tumor-suppressor miRNAs in XPO5 mutant cells is associated with the upregulation of their respective target oncoproteins that is reverted by the transfection of wild-type XPO5, such as we observed for EZH2 (miR-26a), MYC (miR-192, miR-215, let-7, and miR-24), and K-RAS (miR-192, miR-215, and let-7) ( Figure 5D ). One of the best examples was the miR-200 family of tumor-suppressor miRNAs that targets ZEB1, a known inhibitor of E-cadherin (CDH1) expression (Burk et al., 2008 Figure 5E ).
Most notably, the ectopic expression of XPO5 in the mutant cells had cancer growth-inhibitor features (Figure 6 ). Upon transfection of the wild-type XPO5 in HCT-15 mutant colorectal cancer cells, the cells proved less viable in the MTT assay (Figure 6A) and had a markedly reduced percentage colony formation density ( Figure 6B) . Transfection of the XPO5
Mut form in HCT-15 cells was unable to reduce cell viability ( Figure 6A ) and had no impact on the colony formation assay ( Figure 6B ). Overexpression of XPO5 in the wild-type XPO5 colorectal cancer cell line RKO was unable to reduce cell viability ( Figure S5 ), underscoring the specific growth-inhibitory effect of XPO5 only in XPO5 mutant cells. We next tested the ability of XPO5 WT -transfected HCT-15 cells to form tumors in nude mice compared with empty vector transfected cells or with the XPO5 Mut form (Figure 6C ; Figure S5 ). HCT-15 XPO5 mutant cells transfected with the empty vector or the mutant gene formed tumors rapidly, but cells with wild-type XPO5 expression had much lower tumorigenicity ( Figure 6C ; Figure S5 ). In sharp contrast, the stable downregulation of XPO5 by the short hairpin RNA approach in cells with wild-type XPO5 (RKO) was associated with increased cell viability ( Figure 6D ), increased colony density formation (Figure 6E) , and enhanced tumorigenicity in nude mice ( Figure 6F ; Figure S5 ). The use of two additional different shRNAs against XPO5 in RKO cells confirmed the observed enhancement of cell viability and colony formation ( Figure S5 ). Most importantly, when we used siRNAs against XPO5 in cancer cells heterozygous for the XPO5 mutation (HCT-15 and DLD-1), we observed that the complete abrogation of XPO5 expression was toxic, according to the XTT and trypan blue assays ( Figure S5 ). These findings are in agreement with the deleterious effects observed upon the full abolishment of other miRNA processing genes such as DICER1 (Bernstein et al., 2003) , where a haploinsufficient tumor-suppressor role has also been proposed (Kumar et al., 2007 Lambertz et al., 2010) . siRNA against the mutant XPO5 transcript in HCT-15 and DLD1 cells did not cause any evident effect in cell viability ( Figure S5 ). Combined siRNAs of wild-type and mutant XPO5 caused a similar cell toxicity in XPO5 mutant cells than the one observed in single siRNA of wild-type XPO5 ( Figure S5 ).
Finally, we sought to measure the frequency of the described XPO5 disruption in human primary tumors. We assessed the XPO5 mutational status of 337 human primary malignancies with microsatellite instability, including colorectal tumors arising in those patients with germline defects in one mismatch repair allele (HNPCC) (n = 38) and apparently sporadic colorectal (n = 211), gastric (n = 58), and endometrial (n = 30) cancers where mismatch repair gene function was somatically inactivated (Table 1) . We found that XPO5 frameshift mutations were present in 22.8% (77 of 337) of the primary tumors analyzed. The described insertion of an ''A'' in the (A) 7 coding microsatellite repeat of exon 32 ( Figure 1A ) was found in 11.6% (39 of 337) of cases. Interestingly, we discovered two other XPO5 frameshift mutations in primary tumors that we did not observe in any cell line: a deletion of an ''A'' in the same (A) 7 coding microsatellite repeat of exon 32 and a deletion of an ''A'' in an (A) 4 repeat of exon 32. These two mutations were present in 30 (8.9%) and 8 (2.4%) cases, respectively. The deletion of an ''A'' in the (A) 7 repeat changes amino acid composition of the protein from amino acids 1179-1193 and truncates the last 11 amino acids (a very well-described target of the miR-200 family of miRNAs). As a secondary effect, the depletion of the transcriptional repressor ZEB1 causes an upregulation of its targets CDH1, CRB3, INADL, and LGL2. Data shown represent mean ± SD, n = 3.
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Deficient Export of Pre-miRNAs of XPO5. The deletion of an ''A'' in the (A) 4 repeat, also present in exon 32, changes the amino acidic composition of the protein from amino acids 1167-1205. We have cloned these two XPO5 mutations identified in the primary tumors and developed the corresponding in vitro and in vivo assays. We have observed that, upon transfection in XPO5 mutant HCT-15 cells, both mutations originate XPO5 proteins that at steady-state levels present nuclear localization, are unable to enhance miRNA processing efficiency, and do not affect cell viability ( Figure S6 ). No single tumor featured more than one mutation, which highlights the functional relevance of each mutational event. Most importantly, none of the 77 tumors with XPO5 mutations had a mutation in TARBP2, the miRNA biogenesis gene also found alter in microsatellite unstable neoplams ), a result that emphasizes the unique role of XPO5 genetic defects in tumorigenesis. No significant differences in XPO5 mutation frequency were found between inherited and sporadic tumors or between tumor types (Table 1) . The described XPO5 mutations were not present in primary colorectal tumors without microsatellite instability (0/42), normal colorectal mucosa (0/50), or in normal lymphocytes from healthy donors (0/80) (Table 1) . Thus, XPO5 mutations are common events in microsatellite unstable tumors from the colon, stomach, and endometrium.
DISCUSSION
It is estimated that about 30% of human genes are putative targets of miRNAs; hence, they exert a critical role in numerous biological processes. Thus, it is not surprising that an aberrant miRNA expression profile occurs in a wide range of human diseases. This is particularly true for human cancer, in which the expression of miRNAs is markedly deregulated (Lu et al., 2005; Cummins et al., 2006) . Like protein-coding genes, miRNAs can act as tumor suppressors (Hammond, 2007) or oncogenes (Esquela-Kerscher and Slack, 2006) . Although the oncogenic role of some particular miRNAs has been clearly demonstrated, increasing evidence supports the concept that global downregulation of mature miRNAs is a common hallmark of human tumors Figure S5 . (Calin and Croce, 2006; Gaur et al., 2007; Lu et al., 2005) . Many explanations can be invoked to explain this phenotype, and, herein, we propose another one: genetic defects in the nuclear export machinery of pre-miRNAs. Our description of inactivating mutations in XPO5, a key gene in the nuclear export of pre-miRNAs (Yi et al., 2003; Lund et al., 2004) , highlights the relevance of an intact export mechanism of miRNA-related molecules to maintain the cellular homeostasis. The relevance of the described genetic alteration in XPO5 in human cancer is supported by the observation of XPO5 deletions in different malignancies (Zhang et al., 2008) and the described accumulation of pre-miRNAs in particular cancer cell lines . From a functional point of view in normal cells, the XPO5 protein continuously traverses the nuclear envelope (Brownawell and Macara, 2002) , for which reason it should be found in the nuclear and cytoplasmic cellular compartments. However, the described XPO5 mutations prevent XPO5 translocation and ''sequester'' pre-miRNAs in the nucleus, clogging miRNA biogenesis and function. Our data are in agreement with Yi et al. (2003) , where the knockdown of XPO5 caused diminished levels of pre-miR-30 in the cytoplasmic fraction. Others have already defined the pre-miRNA structural requirements for binding to XPO5 (Zeng and Cullen, 2004) . Pre-miRNAs are specifically bound by XPO5 acting in concert with the GTP-bound form of the Ran cofactor (Bohnsack et al., 2004) and this pre-miRNA/ XPO5/Ran-GTP ternary complex is recognized by proteins of the nuclear pore complex. The XPO5 mutant cancer form identified is still able to bind to the Ran protein, but binding cooperativity cargo-Ran has been lost due to the impaired pre-miRNA recognition. Thus, subcellular distribution of XPO5 protein is dependent, not only on Ran-GTP binding to its N-terminal region (Bohnsack et al., 2004) , but also to pre-miRNA binding. Interestingly, Okada et al. (2009) has recently described the crystal structure of the complex formed between XPO5/Ran with the premiRNA molecule. Remarkedly, this structural study only modeled residues 1-1082 of the XPO5 protein, therefore leaving uncharacterized the residues altered in the XPO5 Mut form present in cancer, although it was suggested that the C-terminal of XPO5 was flexible (Okada et al., 2009) . It is worth to consider that the pre-miRNA used to prepare the recombinant complex for crystallization was much shorter than the one used in our study, which contains the stem loop and resembles the physiological premiRNA molecule that is exported out of the nucleus. Therefore, it is possible that the C-terminal region of XPO5 contributes to the binding of the pre-miRNA fragment that is not contained in the above mentioned crystal structure, because that section of the pre-miRNA is missing in the reconstituted complex. In fact, the structure deposited in the Protein Data Bank (pdb 3A6P) shows that the C-terminal region is close to the place where the rest of the RNA molecule should be positioned. Alternatively, the cargo-binding defect observed in XPO5 Mut might be associated with a destabilization of the high-affinity conformation of XPO5 for pre-miRNA binding, which is also consistent with our band-shift and isothermal titration microcalorimetry data. Further research is warranted in this area. Interestingly, from a potential translational point of view, the exogenous introduction of wild-type XPO5 in mutant cancer cells is able to restore the physiological nuclear export of premiRNAs, and this XPO5 functional recovery is associated with tumor growth inhibition properties. Most importantly, XPO5 transfection in mutant cells caused upregulation of miRNAs with well-characterized tumor-suppressor features, such as the miR-200 family, let-7a, and miR-26a, a finding that might encourage the development of further strategies to restore the expression of miRNAs with tumor-suppressor activities. The development of more efficient delivery systems, such as adenoassociated virus (AAV) vectors, has enabled significant achievements in this area. For example, systemic AAV-mediated delivery of miR-26a in a hepatocellular carcinoma mouse model results in the remarkable suppression of tumorigenesis without evident toxicity (Kota et al., 2009 ).
In conclusion, we provide evidence that inactivating mutations of the pre-miRNA nuclear export gene XPO5 occur in human tumors with microsatellite instability. The XPO5 mutation causes the trapping of pre-miRNAs in the nucleus and impairs the production of mature miRNAs in cancer cells, a phenotype that is rescued by the reintroduction of the wild-type XPO5 gene. These findings support a role of XPO5, as a candidate haploinsufficient tumor-suppressor gene, and suggest that strategies directed toward stimulating the activity of miRNA processing factors and restoring the production of miRNAs with growth inhibitory activities might have a therapeutic value. Figure S6 .
Cancer Cell
Deficient Export of Pre-miRNAs cytoplasmic RNA were extracted using the Cytoplasmic and Nuclear RNA purification kit from NORGEN following the manufacturer's instructions. All RNA samples were DNase-treated (Turbo DNA-free, Ambion, Austin, TX). TaqMan MiRNA assays were used to quantify the level of mature miRNAs, as previously described ). Pre-miRNAs processing efficiency calculations are provided in Supplemental Experimental Procedures. The miRNA expression study by microarray analysis was developed as previously described 
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His 6 were expressed in E. coli BL21 (DE3) strain. GST fusion Ran was purified on a glutathione-Sepharose column (Amersham Biosciences) and eluted with 50 mM reduced glutathione. Polyhistidine-tagged proteins were purified using nickel-chelating beads (Millipore) and eluted with 200 mM imidazole. Ran/ XPO5 interaction and western blot analysis (monoclonal anti-His-Tag 1:1000, Abcam; monoclonal anti-His-Tag biotin conjugated 1:2000) were done as described (Ching et al., 2006) . Electrophoretic mobility shift assay was done as described (Yi et al., 2003) . In this issue of Cancer Cell, Melo et al. show that mutation of a single allele of the Exportin-5 gene (XPO5) suffices to depress microRNA (miRNA) levels and promote tumorigenesis. Thus, XPO5 joins the ranks of DICER and TRBP as a haploinsufficient tumor suppressor in the miRNA biogenesis pathway.
MicroRNAs are regulatory RNAs that silence mRNAs in a sequence-specific manner. Originally discovered in Caenorhabditis elegans, almost a thousand different human miRNAs are now known to repress a vast array of target mRNAs. As these include both oncogenes and tumor suppressors, dysregulation of miRNAs contributes to various cancers . However, the causes of miRNA dysregulation are frequently unclear, particularly in those tumors where the levels of many or all miRNAs are changed. Possibly, such alterations reflect defects in the general miRNA biogenesis pathway. MicroRNA biogenesis begins with the transcription of long primary miRNAs (Figure 1) (Kim et al., 2009 ). These primiRNAs are processed by the ribonuclease DROSHA (aka RNASEN) and its cofactor DGCR8/Pasha into the hairpinshaped precursor miRNAs. DICER, in a complex with its partners TRBP or PACT, further processes the pre-miRNAs into short RNA duplexes. One of the duplex strands binds to an Argonaute protein to form an miRNA-induced silencing complex (miRISC), which represses target mRNAs through translational repression and degradation.
While pri-miRNA processing is a nuclear event, pre-miRNA processing occurs in the cytoplasm. Thus, pre-miRNAs need to transit from the nucleus into the cytoplasm, a process that requires the nuclear export receptor XPO5. Melo et al. (2010) now identify XPO5 as a haploinsufficient tumor suppressor in a subset of cancers with microsatellite instability (MSI + ).
These cancers are characterized by expansion or contraction of short DNA repeats due to defects in the DNA mismatch repair system (Boland and Goel, 2010) . In protein-coding sequences, frame-shift mutations result, which may render affected proteins nonfunctional and thus drive cancerogenesis through inactivation of tumor suppressor genes. MSI is particularly frequent in colorectal cancer (CRC), where it accounts for a combined total of 15% of sporadic and heritable cases, but also affects other sites. Melo et al. (2010) report that XPO5 is mutated in some MSI + cell lines and primary tumors. Expansion of an (A) 7 microsatellite in exon 32 alters and truncates the protein sequence and prevents XPO5 from both associating with its premiRNA cargo and exiting the nucleus. In XPO5 mut/+ heterozygous cells, less premiRNA was hence accessible to processing by DICER, resulting in decreased mature miRNA levels. The defects appeared to reflect loss, not neomorphic gain, of XPO5 function, since modest overexpression of wild-type XPO5 rescued the pre-miRNA export and processing defects. Interestingly, although the heterozygous XPO5 mutation decreased accumulation of a large fraction ($20%) of detectable miRNAs, many others remained unaffected. It thus appears possible that XPO5 does not bind to pre-miRNAs indiscriminately but has certain substrate preferences, perhaps mediated by sequence or structure. Downregulated miRNAs might then be those that bind poorly to XPO5 and thus cannot compete well for export by limiting amounts of XPO5. Alternatively, additional nuclear export pathways might be available to miRNAs that remained unaffected, as suggested by recent work in C. elegans (Bü ssing et al., 2010) .
Several genes have been identified that are affected by MSI, but it is not always clear which of these are ''driver mutations'' that truly contribute to tumorigenesis and which are ''passenger mutations'' that signal the presence of a DNA repair defect but have little impact on tumorigenesis (Boland and Goel, 2010 ). Knudson's ''two-hit'' model offers a possible distinction (Payne and Kemp, 2005) . It postulates that only inactivation of both alleles of a tumor suppressor genes (the two hits) provides cells with a selective advantage. Hence, true tumor suppressor genes will frequently display loss of heterozygosity (LOH), i.e., lose the remaining wild-type allele, in tumors. By contrast, lack of selective pressure on passenger mutations would typically cause these to remain heterozygous.
By this criterion, XPO5 would miss the bar. XPO5 LOH could be observed neither in cell lines nor primary tumors. However, recent work has suggested that other components of the miRNA biogenesis pathway, DICER and TRBP (encoded by the TARBP2 gene), are haploinsufficient tumor suppressors . In addition, the miRISC components AGO2, TNRC6A, and TNRC6C can be mutated in MSI + cancers (Kim et al., 2010) + cancers are consequences of specific selective pressures on these tumors? Would these mutations be more synergistic with CRC driver mutations than with mutations driving other tumors? Conversely, are XPO5 and TARBP2 subject to increased MSI rates in MSI + mouse models? If so, it may be possible to establish whether miRNA deficiency occurs at a specific point during tumorigenesis, perhaps driving one or more select events on the path to cancer.
Regardless of these possibilities, one important implication of the two studies by Melo et al. ( , 2010 is that almost half of all MSI + tumors carry defects in their miRNA biogenesis machineries: among 337 primary tumor samples analyzed, some 23% carried one of three different microsatellite mutations in exon 32 of XPO5, all of which impaired XPO5 localization and miRNA biogenic activity, and some 26% of 282 primary tumor samples contained either one of two microsatellite mutations found to inactivate TRBP. Mutations in TARBP2 and XPO5 appear mutually exclusive. The presence of mutations in miRNA pathway genes in MSI + cancer samples, albeit at a lower frequency, has also been reported in a separate study of Korean patients (Kim et al., 2010) . This begs the question of whether this pathway just makes a convenient target or whether a deeper (B) Functional pre-miRNA export in XPO5 +/+ wild-type cells sustains the mature miRNA levels that are required to control cell differentiation and proliferation. Impaired pre-miRNA export in XPO5 mut/+ heterozygous mutant cells depletes mature miRNAs and is tumorigenic but can be overcome by expression of additional wild-type XPO5. This, and the fact that partial depletion of XPO5 by RNAi mimics XPO5 mut/+ heterozygosity, is consistent with haploinsufficiency rather than mutant gain of function causing the defects.
underlying rationale exists where miRNA depletion causes particular proliferative or survival advantages in these cancers. Indeed, it seems rather mysterious that a pathway that is considered important to provide robustness to gene expression programs would display itself so little robustness to mutational assault. It will therefore be of particular interest to examine whether haploinsufficiency is a general feature of miRNA pathway genes across various cancer sites and types or more closely restricted to MSI + tumors.
Finally, it remains to be seen whether the new findings can be exploited therapeutically. At this point, short of gene therapy, there seems to be little that can be done to target the XPO5 defect directly so that restoring miRNA accumulation by alternative routes might be a more realistic approach. Provided that only one or few of the deregulated miRNAs are responsible for the tumor-promoting effect of XPO5 mutation, it may be possible to supply them exogenously as miRNA duplexes that would not need to undergo nuclear export. Alternatively, it may be possible to identify a subset of key targets of the deregulated miRNAs that might be amenable to inactivation through classical pharmacological approaches or novel biologics.
T cell precursor malignancies may present as T-lymphoblastic lymphoma (T-LBL) with marked enlargement of lymph nodes or acute T-lymphoblastic leukemia (T-ALL) with little lymph node enlargement. In this issue of Cancer Cell, Feng et al. show that dysregulation of BCL2, AKT signaling, and cell adhesion pathways are hallmarks of T-LBL.
T-lineage lymphoblastic lymphoma (T-LBL) and acute lymphoblastic leukemia (T-ALL) represent up to 15%-25% of cases of ALL in children and adults and exhibit a remarkable spectrum of clinical, pathologic, and genetic features. In contrast to B-progenitor ALL, in which extensive bone marrow involvement at presentation is a near universal feature and significant lymph node enlargement is uncommon, patients with T-lineage disease frequently present with marked lymph node enlargement in the chest (mediastinal masses), often with minimal or absent bone marrow involvement (Figure 1) . Traditionally, patients with a mediastinal mass and less than 25% leukemic cells (blasts) in the bone marrow are deemed to have T-LBL; those with a high marrow burden, T-ALL. While this distinction may appear somewhat arbitrary, a notable observation is that patients with large mediastinal masses frequently exhibit little, if any, evidence of tumor dissemination and marrow involvement, and the basis for this is unknown.
Both T-LBL and T-ALL cases commonly harbor chromosomal rearrangements, submicroscopic DNA copy number alterations, and sequence mutations. These alterations commonly dysregulate or disrupt genes with key roles in hematopoietic development, lymphoid differentiation, cell cycle regulation, and tumor suppression and are key events in leukemogenesis (e.g., rearrangements of T cell antigen receptor genes, HOX11L1 and HOX11L2, TAL1, LYL1, mutation of NOTCH1 and FBXW7, and deletion or mutation of PTEN and WT1) (Aifantis et al., 2008) . However, in contrast to B-progenitor ALL, in which specific genetic alterations such as mutation of the lymphoid transcription factor IKZF1 are strongly associated with poor prognosis (Mullighan et al., 2009 ), identification of features that predict clinical
